新一轮集采大型外企败北,转变策略主攻新型药

2020-08-22 MedSci原创 MedSci原创

此次集采,部分药物与原研药相比价格削减超过90%。

在4+7带量采购制度下,默克、诺华、礼来和辉瑞等多家外企制药巨头在新一轮的集采中纷纷输给了国产制药商,失败的药物包括礼来的精神分裂症药物Zyprexa和辉瑞的伟哥。此次集采中,部分药物与原研药相比价格削减超过90%。

图片来源:新浪财经

本周在上海举行了第三轮国家药品集中采购(集采),一共约有200家国内外企业竞标56种药品。

阿斯利康、赛诺菲和礼来等公司一直设法在新的集采制度下生存,但是不得不提供重大折扣。 而辉瑞在国内的药品业务于2019年4月就开始下滑。

集采制度下迫使大型外企不得不转变策略,“退出老药”,专注于增加新型药物的市场份额。

原始出处:

https://www.fiercepharma.com/pharma/eli-lilly-pfizer-and-merck-among-pharma-giants-to-lose-latest-round-china-procurement

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1735542, encodeId=0d011e3554227, content=<a href='/topic/show?id=6fe998e4074' target=_blank style='color:#2F92EE;'>#集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98740, encryptionId=6fe998e4074, topicName=集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d33912216, createdName=xsm929, createdTime=Wed Jun 16 17:31:46 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027145, encodeId=ac3c202e145c7, content=<a href='/topic/show?id=b41058019ae' target=_blank style='color:#2F92EE;'>#新一轮集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58019, encryptionId=b41058019ae, topicName=新一轮集采)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Wed Dec 16 21:31:46 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812520, encodeId=5e8e81252001, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:06:58 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812471, encodeId=eae78124e1eb, content=不错 点赞收藏学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLNibQE85E0sLrn9iasdRSCTB5e7ow6EC5ETpKiamzthjhFVNLpj6qKIeianjHUhQl32fPQtkdsiatFfLQ/132, createdBy=4d852205064, createdName=红豆豆豆豆, createdTime=Sun Aug 23 19:48:23 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812392, encodeId=fa5d81239261, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:03:36 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812186, encodeId=a7e5812186c7, content=支持支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMGicvCIibmpTjGP9ib0UbxSZX3WSXfVmatTib7lCsOmic1GP3jiaDuic1YxnR4NFFmYS923pvLKXH0GibdA/132, createdBy=ad235260819, createdName=人家四月, createdTime=Sat Aug 22 23:05:27 CST 2020, time=2020-08-22, status=1, ipAttribution=)]
    2021-06-16 xsm929
  2. [GetPortalCommentsPageByObjectIdResponse(id=1735542, encodeId=0d011e3554227, content=<a href='/topic/show?id=6fe998e4074' target=_blank style='color:#2F92EE;'>#集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98740, encryptionId=6fe998e4074, topicName=集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d33912216, createdName=xsm929, createdTime=Wed Jun 16 17:31:46 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027145, encodeId=ac3c202e145c7, content=<a href='/topic/show?id=b41058019ae' target=_blank style='color:#2F92EE;'>#新一轮集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58019, encryptionId=b41058019ae, topicName=新一轮集采)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Wed Dec 16 21:31:46 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812520, encodeId=5e8e81252001, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:06:58 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812471, encodeId=eae78124e1eb, content=不错 点赞收藏学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLNibQE85E0sLrn9iasdRSCTB5e7ow6EC5ETpKiamzthjhFVNLpj6qKIeianjHUhQl32fPQtkdsiatFfLQ/132, createdBy=4d852205064, createdName=红豆豆豆豆, createdTime=Sun Aug 23 19:48:23 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812392, encodeId=fa5d81239261, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:03:36 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812186, encodeId=a7e5812186c7, content=支持支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMGicvCIibmpTjGP9ib0UbxSZX3WSXfVmatTib7lCsOmic1GP3jiaDuic1YxnR4NFFmYS923pvLKXH0GibdA/132, createdBy=ad235260819, createdName=人家四月, createdTime=Sat Aug 22 23:05:27 CST 2020, time=2020-08-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1735542, encodeId=0d011e3554227, content=<a href='/topic/show?id=6fe998e4074' target=_blank style='color:#2F92EE;'>#集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98740, encryptionId=6fe998e4074, topicName=集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d33912216, createdName=xsm929, createdTime=Wed Jun 16 17:31:46 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027145, encodeId=ac3c202e145c7, content=<a href='/topic/show?id=b41058019ae' target=_blank style='color:#2F92EE;'>#新一轮集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58019, encryptionId=b41058019ae, topicName=新一轮集采)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Wed Dec 16 21:31:46 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812520, encodeId=5e8e81252001, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:06:58 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812471, encodeId=eae78124e1eb, content=不错 点赞收藏学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLNibQE85E0sLrn9iasdRSCTB5e7ow6EC5ETpKiamzthjhFVNLpj6qKIeianjHUhQl32fPQtkdsiatFfLQ/132, createdBy=4d852205064, createdName=红豆豆豆豆, createdTime=Sun Aug 23 19:48:23 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812392, encodeId=fa5d81239261, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:03:36 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812186, encodeId=a7e5812186c7, content=支持支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMGicvCIibmpTjGP9ib0UbxSZX3WSXfVmatTib7lCsOmic1GP3jiaDuic1YxnR4NFFmYS923pvLKXH0GibdA/132, createdBy=ad235260819, createdName=人家四月, createdTime=Sat Aug 22 23:05:27 CST 2020, time=2020-08-22, status=1, ipAttribution=)]
    2020-08-23 ms7000000689223974

    讲的很详细,很有用,赞一个

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1735542, encodeId=0d011e3554227, content=<a href='/topic/show?id=6fe998e4074' target=_blank style='color:#2F92EE;'>#集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98740, encryptionId=6fe998e4074, topicName=集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d33912216, createdName=xsm929, createdTime=Wed Jun 16 17:31:46 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027145, encodeId=ac3c202e145c7, content=<a href='/topic/show?id=b41058019ae' target=_blank style='color:#2F92EE;'>#新一轮集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58019, encryptionId=b41058019ae, topicName=新一轮集采)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Wed Dec 16 21:31:46 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812520, encodeId=5e8e81252001, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:06:58 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812471, encodeId=eae78124e1eb, content=不错 点赞收藏学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLNibQE85E0sLrn9iasdRSCTB5e7ow6EC5ETpKiamzthjhFVNLpj6qKIeianjHUhQl32fPQtkdsiatFfLQ/132, createdBy=4d852205064, createdName=红豆豆豆豆, createdTime=Sun Aug 23 19:48:23 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812392, encodeId=fa5d81239261, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:03:36 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812186, encodeId=a7e5812186c7, content=支持支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMGicvCIibmpTjGP9ib0UbxSZX3WSXfVmatTib7lCsOmic1GP3jiaDuic1YxnR4NFFmYS923pvLKXH0GibdA/132, createdBy=ad235260819, createdName=人家四月, createdTime=Sat Aug 22 23:05:27 CST 2020, time=2020-08-22, status=1, ipAttribution=)]
    2020-08-23 红豆豆豆豆

    不错 点赞收藏学习起来

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1735542, encodeId=0d011e3554227, content=<a href='/topic/show?id=6fe998e4074' target=_blank style='color:#2F92EE;'>#集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98740, encryptionId=6fe998e4074, topicName=集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d33912216, createdName=xsm929, createdTime=Wed Jun 16 17:31:46 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027145, encodeId=ac3c202e145c7, content=<a href='/topic/show?id=b41058019ae' target=_blank style='color:#2F92EE;'>#新一轮集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58019, encryptionId=b41058019ae, topicName=新一轮集采)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Wed Dec 16 21:31:46 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812520, encodeId=5e8e81252001, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:06:58 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812471, encodeId=eae78124e1eb, content=不错 点赞收藏学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLNibQE85E0sLrn9iasdRSCTB5e7ow6EC5ETpKiamzthjhFVNLpj6qKIeianjHUhQl32fPQtkdsiatFfLQ/132, createdBy=4d852205064, createdName=红豆豆豆豆, createdTime=Sun Aug 23 19:48:23 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812392, encodeId=fa5d81239261, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:03:36 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812186, encodeId=a7e5812186c7, content=支持支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMGicvCIibmpTjGP9ib0UbxSZX3WSXfVmatTib7lCsOmic1GP3jiaDuic1YxnR4NFFmYS923pvLKXH0GibdA/132, createdBy=ad235260819, createdName=人家四月, createdTime=Sat Aug 22 23:05:27 CST 2020, time=2020-08-22, status=1, ipAttribution=)]
    2020-08-23 ms7000000689223974

    很有用,很不错,谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1735542, encodeId=0d011e3554227, content=<a href='/topic/show?id=6fe998e4074' target=_blank style='color:#2F92EE;'>#集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98740, encryptionId=6fe998e4074, topicName=集采)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d33912216, createdName=xsm929, createdTime=Wed Jun 16 17:31:46 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027145, encodeId=ac3c202e145c7, content=<a href='/topic/show?id=b41058019ae' target=_blank style='color:#2F92EE;'>#新一轮集采#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58019, encryptionId=b41058019ae, topicName=新一轮集采)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Wed Dec 16 21:31:46 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812520, encodeId=5e8e81252001, content=讲的很详细,很有用,赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 20:06:58 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812471, encodeId=eae78124e1eb, content=不错 点赞收藏学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLNibQE85E0sLrn9iasdRSCTB5e7ow6EC5ETpKiamzthjhFVNLpj6qKIeianjHUhQl32fPQtkdsiatFfLQ/132, createdBy=4d852205064, createdName=红豆豆豆豆, createdTime=Sun Aug 23 19:48:23 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812392, encodeId=fa5d81239261, content=很有用,很不错,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Sun Aug 23 13:03:36 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812186, encodeId=a7e5812186c7, content=支持支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLMGicvCIibmpTjGP9ib0UbxSZX3WSXfVmatTib7lCsOmic1GP3jiaDuic1YxnR4NFFmYS923pvLKXH0GibdA/132, createdBy=ad235260819, createdName=人家四月, createdTime=Sat Aug 22 23:05:27 CST 2020, time=2020-08-22, status=1, ipAttribution=)]
    2020-08-22 人家四月

    支持支持

    0

相关资讯

Nat Med:新药有望替代生物治疗治愈乳腺癌

专家说:“许多女性可以通过一种新型的乳腺癌药物来帮助生物治疗,目前只能作为临床试验的一部分。但是,在不久的将来有很大的希望被用于单独治疗乳腺癌”。专家估计,多达五分之一的患者可能受益。

强心药物治疗的最后一道防线

左西孟旦(Levosimendan)是一种新开发的强心类药物,属于钙离子增敏剂,有别于传统的强心药如地高辛类药物、β1受体激动剂、磷酸二酯酶抑制剂(PDE III抑制剂,米力农)等的作用机制,本文将探讨为什么使用左西孟旦、什么类型的患者可以使用,以及如何使用左西孟旦。

Cell:新型药物治疗恢复耳聋小鼠部分听力

“我们现在能恢复部分听力,特别是较低频率的声音,并救活一部分感觉毛细胞,”美国国立卫生研究院国家耳聋和其他沟通障碍研究所(NIDCD)人类分子遗传实验室主任Thomas B. Friedman博士说。“如果这种小分子药物对人类DFNA27型耳聋有效,那么它将有可能治疗其他遗传学渐进性听力受损。”

J Clin Invest:新型药物可有效抑制产后乳腺癌

在所有的乳腺癌中大约有25%的乳腺癌会在女性怀孕后的2至5年内发生,这些产后肿瘤更易于扩散并且转移至机体其它部位,从而增加患者死亡的风险。近日一项刊登在国际杂志Journal of Clinical Investigation上的研究报告中,来自伊利诺伊大学的科学家们就揭开了引发产后妇女乳腺肿瘤发生转移的细胞活性机理。 Rebecca Cook博士表示,患乳腺癌对于这些刚生完小孩儿的妈妈们来

治疗高血压:谁应该用新药?谁应该用老药?

高血压一旦发生,就开始对人体产生危害。此病一经诊断,就应尽早采取切实有效的治疗手段。

肝炎防治挑战依旧 新型药物获批上市

2018年7月28日是第8个世界肝炎日,世界卫生组织确定的宣传主题为“检测治疗肝炎”。日前,中国肝炎防治基金会召开了“2018年世界肝炎日宣传大会”和“第二届中国肝炎论坛”。世界卫生组织驻华代表处利千基博士表示,慢性乙型肝炎和丙型肝炎是我国乃至全球面临的挑战,影响到全球3.25亿人,同时二者是引起肝癌的根源,每年导致134万人死亡。据估算,我国乙肝病毒携带者约9000万人,丙肝病毒感染者约7